Skip to main
GHRS

GHRS Stock Forecast & Price Target

GHRS Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

GH Research is expected to continue its positive momentum as they approach initiation of their pivotal Phase 3 trial for GH001 in treatment-resistant depression (TRD). The company's recent achievements, such as publishing positive Phase 2b results and completing enrollment in Phase 1 trials, demonstrate progress towards their goal of developing a practice-changing treatment for depression. With a strong portfolio and a healthy cash balance, GH Research has the potential to be a leader in the biopharmaceutical industry and create significant value for investors.

Bears say

GH Research is a clinical-stage biopharmaceutical company focused on developing mebufotenin therapies for Treatment-Resistant Depression (TRD). With only a single segment of Research and Development, and a lack of meaningful competitive programs in China, there may be limited potential for revenue growth. Additionally, the company's decision to keep details of their aerosolized device/dosing regimen secret for competitive reasons may indicate potential issues or concerns.

GHRS has been analyzed by 8 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of GH Research PLC and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About GH Research PLC (GHRS) Forecast

Analysts have given GHRS a Buy based on their latest research and market trends.

According to 8 analysts, GHRS has a Buy consensus rating as of Aug 8, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $43.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $43.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

GH Research PLC (GHRS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.